BiotechTube
Home/Pipeline/Ex vivo dendritic-cell activation

Ex vivo dendritic-cell activation

Not specified

Phase 2Active

Key Facts

Indication
Not specified
Phase
Phase 2
Status
Active
Company
eTheRNA immunotherapies

About eTheRNA immunotherapies

eTheRNA immunotherapies is a platform-driven RNA-LNP technology company based in Niel, Belgium. It leverages decades of scientific expertise to offer integrated capabilities in RNA chemistry, LNP delivery technologies, and GMP manufacturing, supporting partners from discovery through clinical development. The company operates through a dual business model of technology/product partnering and is advancing its own clinical-stage pipeline, including an intratumoral oncology platform now in clinical testing with partner Almirall.

View full company profile

Therapeutic Areas

OncologyInfectious DiseasesImmunology

Other Not specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved